Loading stock data…
$2.11-0.05 (-2.37%)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Larimar Therapeutics, Inc. in the Healthcare sector is trading at $2.11 with a market capitalization of $337M. Wall Street consensus targets $14.40 (10 analysts), implying a +582.8% move over the next 12 months. The stock is currently near its 52-week low of $2.06, remaining 45.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.35M↓ | -$31.12M↑ | -$64.02M↓ | -$49.50M↓ | -$27.79M |
| Net Income | -$32.78M↓ | -$29.61M↑ | -$62.50M↓ | -$47.71M↓ | -$26.18M |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clini...